

Press release - translation

Lund 29 April 2021

Scandinavian ChemoTech has received a date for a final revision of its CE marking

ChemoTech has today received an assigned date for the final revision of the CE marking of the IQwave™ and TSE platform from its Notified Body.

ChemoTech's Notified Body has today given the Company a date for a final revision, which is very positive and signals that the Notified Body sees that a successful revision may be possible. The final revision of the Company's CE marking will begin on May 10th; however, we have not yet received a date for when the outcome of the revision will be announced.

"It is very gratifying that our Notified Body has granted a final revision of the IQwave and TSE platform. However, we would like to note that this does not guarantee a positive outcome and we have continued intensive work ahead of us until that day." - says ChemoTech's CEO Mohan Frick

ChemoTech has for a long time received several orders and distributor agreements in both Asia and Europe, which after a successful CE marking will be able to be initiated.

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,
E-mail: certifiedadviser@penser.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Thursday 29th of April 2021 at 21.00 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se